AZD0516
AZD0516 is a first-in-class antibody-drug conjugate (ADC) targeting six-transmembrane epithelial antigen of the prostate-2 (STEAP2) . The anti-STEAP2 monoclonal antibody (mAb) is conjugated via interchain cysteines to a maleimide-reactive, β-glucuronidase-cleavable linker (HY-173635) bearing the topoisomerase 1 inhibitor, Exatecan (HY-13631) . AZD0516 can be used for the study of prostate cancer[1].
Product Specifications
UNSPSC
12352211
Target
Antibody-Drug Conjugates (ADCs) ; Topoisomerase
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
95.82
Smiles
[AZD0516]
References & Citations
[1]1158-Preclinical characterization of AZD0516, a novel STEAP2 antibody-drug conjugate (ADC) for the treatment of prostate cancer. AACR Annual Meeting 2025 Itinerary Planner Home.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6256450-01 0.1 mL
AMP Activated Protein Kinase alpha1/2 (AMPKa1/2) (MaxLight 750) (Drosophila)
Ask
View Details 
MBS6256450-02 5x 0.1 mL
AMP Activated Protein Kinase alpha1/2 (AMPKa1/2) (MaxLight 750) (Drosophila)
Ask
View Details 
485195 100 µL
LYN (Tyrosine-Protein Kinase Lyn, V-Yes-1 Yamaguchi Sarcoma Viral Related Oncogene Homolog)
Ask
View Details MBS6225787-01 0.1 mL
Cytokeratin, Basic (Type II or HMW) (BSA & Azide Free) (MaxLight 650)
Ask
View Details